LLY

1,070.33

+0.82%↑

JNJ

206.53

-1.07%↓

ABBV

229.06

+2.46%↑

UNH

327.58

-0.05%↓

AZN

91.41

+0.61%↑

LLY

1,070.33

+0.82%↑

JNJ

206.53

-1.07%↓

ABBV

229.06

+2.46%↑

UNH

327.58

-0.05%↓

AZN

91.41

+0.61%↑

LLY

1,070.33

+0.82%↑

JNJ

206.53

-1.07%↓

ABBV

229.06

+2.46%↑

UNH

327.58

-0.05%↓

AZN

91.41

+0.61%↑

LLY

1,070.33

+0.82%↑

JNJ

206.53

-1.07%↓

ABBV

229.06

+2.46%↑

UNH

327.58

-0.05%↓

AZN

91.41

+0.61%↑

LLY

1,070.33

+0.82%↑

JNJ

206.53

-1.07%↓

ABBV

229.06

+2.46%↑

UNH

327.58

-0.05%↓

AZN

91.41

+0.61%↑

Search

PerkinElmer Inc

Abrir

SetorSaúde

0

Visão Geral

Variação de preço das ações

24h

Atual

Mín

Máximo

Indicadores-chave

By Trading Economics

Rendimento

-8.6M

47M

Vendas

-21M

699M

P/E

Médio do Setor

51.072

76.798

EPS

1.18

Rendimento de Dividendos

0.28

Margem de lucro

6.675

Funcionários

11,000

EBITDA

-14M

181M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+14.93% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

0.28%

2.37%

Próxima data de ex-dividendo

16 de jan. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

223M

12B

Abertura anterior

0

Fecho anterior

0

Sentimento de Notícias

By Acuity

23%

77%

43 / 374 Ranking em Healthcare

PerkinElmer Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

18 de dez. de 2025, 23:54 UTC

Ações em Alta

Stocks to Watch: Nike, Cassava Sciences, KB Home

18 de dez. de 2025, 23:51 UTC

Ganhos

Nike Sales Tick Up in 2Q; China Weakness Persists -- Update

18 de dez. de 2025, 23:39 UTC

Grandes Movimentos do Mercado

Cassava Sciences Shares Fall After FDA Places Hold on Epilepsy Drug Trial

18 de dez. de 2025, 22:57 UTC

Aquisições, Fusões, Aquisições de Empresas

TikTok Signs Agreement for Sale of U.S. Unit, Axios Reports, Citing a Memo

18 de dez. de 2025, 21:40 UTC

Ganhos

Nike Sales Tick Up, But China Weakness Persists

18 de dez. de 2025, 23:45 UTC

Conversa de Mercado

Gold Steady, Supported by Fed Rate-Cut Prospects -- Market Talk

18 de dez. de 2025, 23:37 UTC

Conversa de Mercado
Ganhos

Nike 2Q Results Fail to Convince Investors of Recovery -- Market Talk

18 de dez. de 2025, 23:36 UTC

Conversa de Mercado

Nikkei May Rise, Tracking Wall Street's Rally -- Market Talk

18 de dez. de 2025, 23:03 UTC

Aquisições, Fusões, Aquisições de Empresas

Mitsubishi Materials: Impact on Consolidated Results for FY Ending March 2026 Likely to be Immaterial

18 de dez. de 2025, 23:02 UTC

Aquisições, Fusões, Aquisições de Empresas

Mitsubishi Materials: To Acquire 4,448 Common Shares, 13,771 Preferred Shares of Co.

18 de dez. de 2025, 23:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Mitsubishi Materials: Investment to Strengthen Recovery Network in U.S.

18 de dez. de 2025, 22:59 UTC

Aquisições, Fusões, Aquisições de Empresas

Mitsubishi Materials: Investment to Contribute to Expanding Collection Volume of Secondary Raw Material

18 de dez. de 2025, 22:58 UTC

Aquisições, Fusões, Aquisições de Empresas

SpaceX Could Go Public by Merging With EchoStar. It Isn't a Crazy Idea. -- Barrons.com

18 de dez. de 2025, 22:57 UTC

Aquisições, Fusões, Aquisições de Empresas

Mitsubishi Materials: Elemental USA E-Waste Operates E-Waste Recycling Business in U.S.

18 de dez. de 2025, 22:56 UTC

Aquisições, Fusões, Aquisições de Empresas

Mitsubishi Materials: To Acquire Portion of Shares of Elemental USA E-Waste & ITAD

18 de dez. de 2025, 22:55 UTC

Ganhos

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 de dez. de 2025, 21:59 UTC

Ganhos

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 de dez. de 2025, 21:50 UTC

Conversa de Mercado
Ganhos

Tech, Media & Telecom Roundup: Market Talk

18 de dez. de 2025, 21:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

18 de dez. de 2025, 21:35 UTC

Ganhos

FedEx's Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

18 de dez. de 2025, 21:31 UTC

Ganhos

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 de dez. de 2025, 21:15 UTC

Ganhos

Nike 2Q Europe, Middle East & Africa Rev $3.39B >NKE

18 de dez. de 2025, 21:15 UTC

Ganhos

Nike 2Q Greater China Rev Down 17% >NKE

18 de dez. de 2025, 21:15 UTC

Ganhos

Nike 2Q EPS 53c >NKE

18 de dez. de 2025, 21:15 UTC

Ganhos

Nike 2Q Apparel Rev $3.91B >NKE

18 de dez. de 2025, 21:15 UTC

Ganhos

Nike 2Q Equipment Rev $550M >NKE

18 de dez. de 2025, 21:15 UTC

Ganhos

Nike 2Q N Amer Rev $5.63B >NKE

18 de dez. de 2025, 21:15 UTC

Ganhos

Nike 2Q Footwear Rev $7.66B >NKE

18 de dez. de 2025, 21:15 UTC

Ganhos

Nike 2Q Asia Pacific & Latin America Rev Down 4% >NKE

18 de dez. de 2025, 21:15 UTC

Ganhos

Nike 2Q Greater China Rev $1.42B >NKE

Comparação entre Pares

Variação de preço

PerkinElmer Inc Previsão

Preço-alvo

By TipRanks

14.93% parte superior

Previsão para 12 meses

Média 111.22 USD  14.93%

Máximo 123 USD

Mínimo 100 USD

Com base em 10 analistas de Wall Street que oferecem metas de preço de 12 meses para PerkinElmer Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

10 ratings

5

Comprar

5

Manter

0

Vender

Sentimento

By Acuity

43 / 374 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre PerkinElmer Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat